Background {#Sec1}
==========

Globally, allergic rhinitis (AR) is a common, systemic allergic disease, with a prevalence of up to 25% in children and 40% in adults \[[@CR1]\]. Among patients with AR, other allergic disorders are frequently comorbid \[[@CR2]\]. Between 15% and nearly 40% of patients with AR have comorbid asthma, whereas asthma prevalence in the general population is approximately 7% \[[@CR1], [@CR3]\].

Among patients with AR who visited a general practitioner, the majority---more than 90%---have moderate-to-severe intermittent or persistent disease \[[@CR4]\]. Many patients with moderate-to-severe AR have poorly controlled asthma \[[@CR3]\], which may be attributable in part to lower airway inflammation \[[@CR3]\]. In a survey of 520 patients with asthma, asthma was significantly less likely to be controlled in patients with moderate-to-severe, persistent AR compared with those with intermittent AR (65.7% vs 20.4%; *P* \< 0.01) \[[@CR4]\]. Furthermore, patients with AR and asthma comorbidity have higher healthcare resource utilization, including clinic visits, hospitalizations, and pharmacy costs over a 12-month time period \[[@CR5]\]. Direct costs of AR are significantly higher for patients with mild-persistent asthma (€719) or moderate-persistent asthma (€799) than for the general population with AR (€554) \[[@CR6]\].

Treatment of AR may concurrently improve AR and asthma symptoms in patients with comorbid disease \[[@CR7]--[@CR9]\]. In a past study, failure to manage AR symptoms was associated with increased use of asthma medications \[[@CR7]\]. When patients with moderate-to-severe AR forgot to use their AR medication, more than half of those patients reported having to increase use of asthma reliever medications and 19.5% reported a need to increase asthma controller medication use \[[@CR7]\]. Furthermore, in observational studies, AR treatment has been shown to improve upper and lower airway outcomes and decrease the risk for asthma-related hospitalization and emergency department visits by half \[[@CR8], [@CR9]\].

Treatments for AR include oral H~1~ antihistamines, intranasal corticosteroids (INCS), or intranasal antihistamines (INAH) \[[@CR1]\]. Despite the wide variety of medication options available, many patients are dissatisfied with their AR treatment, resulting in poor adherence \[[@CR10]\]. Therefore, combination therapies may improve satisfaction by reducing medication burden in patients with moderate-to-severe, persistent AR symptoms. In the Allergic Rhinitis and its Impact on Asthma (ARIA) 2016 guideline update, combination treatment with INCS and INAH is recommended for patients with AR \[[@CR1]\].

Azelastine hydrochloride has been formulated with fluticasone propionate in a single intranasal spray (MP-AzeFlu; Dymista^®^) for the treatment of AR \[[@CR11]\]. Compared with fluticasone propionate or azelastine hydrochloride alone, MP-AzeFlu resulted in significantly greater improvements in AR symptoms, including nasal congestion, one of the most bothersome and prevalent symptoms of AR, \[[@CR12]--[@CR14]\] nasal cell inflammation \[[@CR15]\], loss of smell \[[@CR16]\], and nasal hyperreactivity \[[@CR17]\]. Relative to individual dosing of both an INAH and INCS, MP-AzeFlu was also associated with lower pharmacy costs and total costs in a prior database analysis \[[@CR18]\].

The purpose of this analysis of a real-world study was to evaluate the effect of MP-AzeFlu on asthma symptoms and frequency of use of asthma reliever medication in patients with comorbid AR and asthma.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a multinational, multicenter, prospective, noninterventional, real-life study conducted in 6 European countries: Austria, Germany, Czech Republic, Hungary, Netherlands, and Ireland. The study ran from February 21, 2018, to April 30, 2019. Ethics approval was obtained according to guidelines and procedures of the respective countries. Physicians who were usually involved in the management of AR and routinely used a visual analog scale (VAS) for symptom assessment in patients with AR were invited to participate in the study. Participating physicians included general practitioners, allergists, otorhinolaryngologists, pulmonologists, dermatologists, and pediatricians.

The study consisted of an inclusion visit (day 0) and a control visit after about 14 days, allowing for some flexibility depending on usual clinical practice. Patients received patient cards at the inclusion visit to record AR symptoms, asthma symptoms, and other outcomes using a VAS. Physicians collected patient cards at the control visit, on or around day 14 or by mail.

Participants {#Sec4}
------------

Physicians enrolled patients with moderate-to-severe seasonal or perennial AR according to ARIA criteria, for whom MP-AzeFlu was prescribed for the first time. Decisions to include patients in the study were made by the physicians independently from and after the decision to prescribe MP-AzeFlu to the patient.

Inclusion criteria included first-time prescription of MP-AzeFlu according to the summary of product characteristics, age 12 years or older, moderate-to-severe AR according to ARIA criteria \[[@CR19]\], acute symptoms of AR on the day of inclusion (AR symptoms VAS ≥ 50 mm), written informed consent by the patient and (if applicable) caregiver for patients younger than 18 years, ability to understand the instructions for use of MP-AzeFlu according to the summary of product characteristics and patient leaflet, and ability to return the completed patient card.

Exclusion criteria included known allergic reactions to MP-AzeFlu or any of its ingredients, pregnancy or planned pregnancy, breastfeeding, inability to provide informed consent, or missing consent.

Study treatment {#Sec5}
---------------

All patients received MP-AzeFlu. MP-AzeFlu was dosed as outlined in the country-specific summary of product characteristics: 1 spray in each nostril twice daily (total daily dose: 548 µg azelastine hydrochloride and 200 µg fluticasone propionate) for 2 weeks. Physicians ensured that the patient properly understood the instructions for use, as specified in the summary of product characteristics and patient information leaflet.

Study measures/outcomes {#Sec6}
-----------------------

On day 0, the physician documented patient demographics, AR symptoms, and previous treatments of AR in an electronic case report form. Patient recollections of their AR symptoms over the past 24 h were measured using a printed single-line VAS (AR-VAS) in the patient card, ranging from "not at all bothersome" (0 mm) to "extremely bothersome" (100 mm). AR symptom severity VAS scores and, for patients who suffered from asthma, asthma symptom severity VAS scores, were documented on the patient's card on days 0, 1, 3, 7, and \~ 14. Response was defined as an AR-VAS rating \< 50 mm (indicating controlled AR) \[[@CR20]\] at least once during the study.

On days 0, 7, and \~ 14, patients assessed their sleep quality and troublesomeness in daily activities over the past 7 days, from "not at all troubled" (0 mm) to "extremely troubled" (100 mm). For patients who suffered from asthma, information on frequency of use of asthma reliever medication was collected at baseline. At the end of the documentation period (day \~ 14), the self-reported change in the frequency of use of asthma reliever medication was recorded as significantly reduced, reduced, equal, increased, or significantly increased. All suspected adverse drug reactions were documented in the case reports.

Statistical methods {#Sec7}
-------------------

Subpopulation analyses were performed for patients with AR but no asthma and for patients with AR and asthma comorbidity. The responder rate was calculated for the study population. Statistical analyses were performed using the statistical software package SAS (SAS Institute Inc.; Cary, NC, USA) version 9.4 or higher.

Results {#Sec8}
=======

Study population {#Sec9}
----------------

Of 1154 enrolled patients, 51 were excluded from data analysis because their data had not been confirmed by the investigator. The 1103 remaining patients were included in the safety analysis. A total of 267 patients listed asthma as a comorbidity. Patient demographics and baseline characteristics are detailed in Table [1](#Tab1){ref-type="table"}.Table 1Patient Baseline DemographicsBaseline characteristicsTotal study population (N = 1103)AR with no asthma (n = 836)AR with asthma (n = 267) Gender, n (%)  Male474 (43.0)355 (42.5)119 (44.6)  Female624 (56.6)478 (57.2)146 (54.7)  Missing5 (0.5)3 (0.4)2 (0.8) Age, n (%)  12--17 years82 (7.4)67 (8.0)15 (5.6)  18--65 years937 (85.0)711 (85.0)226 (84.6)  \> 65 years84 (7.6)58 (6.9)26 (9.7) Allergic sensitization (number of allergens), n (%)  1178 (16.1)152 (18.2)26 (9.7)  2--5570 (51.7)428 (51.2)142 (53.2)  \> 5176 (16.0)96 (11.5)80 (30.0)  Unknown179 (16.2)160 (19.1)19 (7.1) Type of AR, n (%)  Perennial only120 (10.9)102 (12.2)18 (6.7)  Seasonal only435 (39.4)354 (42.3)81 (30.3)  Perennial and seasonal444 (40.3)285 (34.1)159 (59.6)  Missing104 (9.4)95 (11.4)9 (3.4) Allergic comorbidities, n (%)  Asthma267 (24.2)0 (0)267 (100)  Dermatitis/eczema127 (11.5)90 (10.8)37 (13.9)  Food allergy/allergies109 (9.9)81 (9.7)28 (10.5)  Severe allergic reactions30 (2.7)18 (2.2)12 (4.5)  None593 (53.8)593 (70.9)0  Missing89 (8.1)89 (10.6)0 Baseline AR-VAS scores, mean (SD)  AR-VAS scores73.2 (13.4)72.8 (13.4)74.1 (13.5) Previous symptomatic AR treatments since last year, n (%)  Oral, nonsedating H~1~-antihistamine506 (45.9)  Intranasal corticosteroid471 (42.7)  Intranasal decongestant191 (17.3)  Intranasal H~1~-antihistamine177 (16.0)  Oral, first-generation H~1~-antihistamine162 (14.7)  Ocular H~1~-antihistamine133 (12.1)  Oral or nebulized corticosteroid99 (9.0)  Intranasal mast cell stabilizer62 (5.6)  Oral leukotriene antagonist50 (4.5)  Ocular mast cell stabilizer42 (3.8)  Oral decongestant26 (2.4)  Other54 (4.9)  Unknown24 (2.2)  None164 (14.9)*AR* indicates allergic rhinitis, *SD* standard deviation, *VAS* visual analog scale^a^Percentages may not equal 100 due to rounding

AR symptom response {#Sec10}
-------------------

In the total study population, all 1103 patients were included in the responder rate analysis. Among the 915 patients reporting previous AR treatment, the most commonly used symptomatic AR treatments were oral, nonsedating H~1~-antihistamine (n = 506; 45.9%), INCS (n = 471; 42.7%), intranasal decongestant (n = 191; 17.3%), INAH (n = 177; 16.0%), oral, first-generation H~1~-antihistamine (n = 162; 14.7%), and ocular H~1~-antihistamine (n = 133; 12.1%).

Treatment response was defined as an AR-VAS score \< 50 mm, the cutoff that differentiates controlled AR from uncontrolled AR \[[@CR20]\], on any 1 day. A total of 944 patients \[86.6%; 95% confidence interval (CI), 84.5--88.5%) met the response criteria, including 728 patients without asthma (88.1%; 95% CI 85.8--90.2%) and 216 patients with asthma (81.8%; 95% CI 76.7--86.0%). Over the course of treatment, the mean \[standard deviation (SD)\] VAS decreased by 46.2 (23.3) mm from baseline to the last day (Fig. [1](#Fig1){ref-type="fig"}). The mean (SD) change in AR-VAS over the study period for patients with AR without asthma was − 46.4 (22.9) mm; for AR with comorbid asthma, it was − 45.3 (25.2) mm. For patients with and without comorbid asthma, the AR-VAS change from baseline was significant at every time point (*P* \< 0.0001). Furthermore, no significant differences were observed between patients with and without asthma in AR-VAS change at any time point.Fig. 1Changes in AR-VAS Scores With MP-AzeFlu Treatment. Time course of mean (SEM) VAS scores of AR symptoms from day 0 to the last trial day (**a**) in the total study population and (**b**) stratified by the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scale

Asthma symptom response {#Sec11}
-----------------------

Among the subpopulation of patients with asthma, patients rated their asthma symptoms on a VAS. The mean (SD) asthma-VAS score decreased from 48.9 (29.3) mm at baseline to 24.1 (21.9) mm on the last day, resulting in a mean change of − 25.7 (26.0) mm (Fig. [2](#Fig2){ref-type="fig"}). Changes from baseline for AR symptoms and asthma symptoms were moderately correlated (Pearson correlation coefficient, 0.47; *P* \< 0.0001).Fig. 2Changes in Asthma-VAS Scores With MP-AzeFlu Treatment. Time course of mean (SEM) VAS of asthma symptoms from day 0 to lthe last trial day among patients with comorbid AR and asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scale

Participants with asthma reported using reliever medication a mean of 5.1 times during the week before treatment. Self-reported data regarding frequency of asthma reliever medication use during the study period were available for 241 patients (85.0%). A total of 139 patients (57.6%) reported that the frequency of asthma reliever use was either considerably reduced or reduced. In addition, 93 patients (38.6%) reported no change, and 9 patients (3.7%) reported an increased frequency of asthma reliever medication use.

Quality-of-life measurements {#Sec12}
----------------------------

### Troublesomeness of sleep {#Sec13}

Changes in quality-of-life measurements are reported in Fig. [3](#Fig3){ref-type="fig"} through Fig. [6](#Fig6){ref-type="fig"}. In the whole study population, mean (SD) troublesomeness with sleep quality VAS score significantly decreased by − 33.7 (28.1) mm from day 0 to the last day (*P *\< 0.0001). Similarly, among the subpopulation of AR with asthma, mean (SD) troublesomeness with sleep quality VAS score decreased by 34.6 (29.1) mm from day 0 to the last day. Among the population without asthma, mean (SD) troublesomeness with sleep quality VAS score decreased by − 32.7 (28.6) mm from baseline (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Changes in Troublesomeness of Sleep Quality VAS Scores With MP-AzeFlu Treatment. Time course of mean (SEM) VAS of change of troublesomeness of sleep quality from day 0 to the last trial day (**a**) in the total study population and (**b**) in subpopulations according to the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scale

### Troublesomeness of daily activities {#Sec14}

The mean (SD) troublesomeness of daily activities at work or school VAS score significantly decreased by 35.2 (25.6) mm in the whole study population (*P* \< 0.0001). In the subpopulation of AR with asthma, the mean (SD) troublesomeness of daily activities at work or school VAS score decreased by 34.3 (27.5) mm. For patients without asthma, the mean (SD) decrease from baseline in troublesomeness of daily activities was 34.7 (26.3) mm (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Changes in Troublesomeness of Daily Work and School Activities VAS Scores with MP-AzeFlu Treatment. Time course of mean (SEM) VAS of change of troublesomeness of daily work and school activities from day 0 to the last trial day (**a**) in the total study population and (**b**) in subpopulations according to the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scale

Furthermore, in the whole study population, the mean (SD) troublesomeness with daily social activities VAS score significantly decreased by 33.2 (25.8) mm from baseline to the last day (*P* \< 0.0001), whereas the mean (SD) decrease in the asthma population was 32.6 (29.2) mm. Among patients with no asthma, the mean (SD) change in social activities VAS score was − 32.7 (26.1) mm (Fig. [5](#Fig5){ref-type="fig"}). Finally, mean (SD) troublesomeness with daily outdoor activities VAS scores significantly decreased by 40.0 (27.2) mm, 40.2 (30.9), and 39.2 (28.0) mm in the general study population (*P* \< 0.0001), asthma subpopulation, and no asthma subpopulation, respectively (Fig. [6](#Fig6){ref-type="fig"}).Fig. 5Changes in Troublesomeness of Sleep Quality VAS Scores With MP-AzeFlu Treatment. Time course of mean (SEM) VAS of change of troublesomeness of sleep quality from day 0 to the last trial day (**a**) in the total study population and (**b**) in subpopulations according to the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scaleFig. 6Changes in Troublesomeness of Daily Outdoor Activities VAS Scores With MP-AzeFlu Treatment. Time course of mean (SEM) VAS of change of daily outdoor activities from day 0 to the last trial day (**a**) in the total study population and (**b**) in subpopulations according to the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog scale

Safety {#Sec15}
------

Among the safety analysis population, 20 nonserious adverse drug reactions were reported in 14 patients (1.3%). The most frequent adverse events included epistaxis (0.4%), dysgeusia (0.3%), headache (0.2%), and dyspnea (0.2%). Among 267 patients with comorbid asthma, 5 nonserious adverse drug reactions were reported in 3 patients (1.1%), which was similar to the total population. No serious adverse drug reactions occurred.

Discussion {#Sec16}
==========

This was the first multicenter, prospective, noninterventional, real-life study to evaluate the effect of AR treatment with MP-AzeFlu on asthma symptom severity and reliever medication use. A total of 24% of patients with AR in this study reported comorbid asthma, which is comparable with literature rates of 15% to 38% \[[@CR1]\]. We showed that patients with moderate-to-severe AR and comorbid asthma treated with MP-AzeFlu had similarly improved AR symptom severity compared with patients with AR alone. Patients with and without comorbid asthma also experienced improved quality of life with MP-AzeFlu treatment. For patients with asthma, asthma symptom severity and asthma reliever medication use decreased from baseline.

In general, improvements in AR-VAS scores and quality-of-life measures were comparable for patients with and without asthma. This is particularly notable given that the subpopulation with comorbid asthma had numerically higher rates of more severe AR symptoms. Although significance testing was not performed across populations, the AR with asthma group had a higher rate of both perennial and seasonal AR and allergic sensitization to more than 5 allergens. Baseline AR-VAS scores, however, were only modestly higher in the group with asthma. These data suggest MP-AzeFlu treatment may have similar effectiveness in populations with and without asthma and with varying levels of AR severity.

VAS scores were used to assess AR symptom severity, asthma symptom severity, and quality-of-life measures in this study. Advantages of VAS measurements include a high degree of resolution, with repeat measures offering the opportunity to identify even small changes within and among individual patients and groups of patients \[[@CR21]\]. In addition, VAS scores are good tools for measuring continuous variables, such as AR and asthma symptoms \[[@CR21]\]. In past studies, VAS scores have been shown to correlate well with the severity of AR according to ARIA guidelines \[[@CR22], [@CR23]\]. A cutoff variation of 23 mm for VAS was shown to correlate well with the established cutoff of 0.5 for the Rhinoconjunctivitis Quality of Life Questionnaire \[[@CR23]\]. Moreover, a change of 30 mm was always correlated with positive changes in quality-of-life parameters \[[@CR23]\]. In the present study, changes in AR-VAS scores from baseline to the last day exceeded this cutoff for all endpoints in the safety population and the comorbid asthma population, suggesting meaningful changes in symptoms and quality of life.

VAS scores are not only useful in clinical practice for stratifying patients and monitoring response; they have also been used as evaluation parameters in randomized controlled trials of AR treatment. In 2 studies of AR evaluating treatment with INAH, VAS scores discriminated between placebo and treatment groups better than total symptom scores \[[@CR24], [@CR25]\]. In this study, the mean change in AR-VAS from baseline to the last day suggests a shift from uncontrolled to controlled AR and severe to mild AR.

Although VAS scores are less commonly used for evaluation of asthma symptoms, they have nonetheless been shown to be valid measures for predicting asthma control and lung function \[[@CR26]--[@CR28]\]. When VAS was evaluated in the morning and evening in adolescent patients with asthma, average VAS scores were significantly correlated with both asthma control (r = 0.65, *P* \< 0.001) and FEV~1~ (r = − 0.38, *P* = 0.029) \[[@CR26]\]. In a study of Japanese patients, Global Initiative for Asthma--defined control levels were discriminated by VAS score cutoff points of 1.50 cm (controlled), 4.79 cm (partly controlled), and 7.19 cm (uncontrolled) \[[@CR28]\]. According to these cutoffs, the asthma severity VAS scores were suggestive of uncontrolled asthma at baseline, which is further supported by the use of more than 5 puffs of reliever medication on average in the week before treatment with MP-AzeFlu. With MP-AzeFlu treatment, asthma control improved by the last day to partly controlled in the majority of patients (median 20.0 mm) and to controlled in at least 25% of patients (low quartile 5.0 mm). These data are further supported by the reduced use of asthma reliever medication at study conclusion. Several studies have shown that the use of INCS can improve asthma symptoms in patients with comorbid AR through the treatment of upper airway inflammation, which indirectly decreases bronchial hyperreactivity \[[@CR29], [@CR30]\]. Therefore, improvement in asthma symptoms with MP-AzeFlu treatment could be attributed to the improved control of AR symptoms, decreased airway inflammation, or, most likely, a combination of the two, which is supported by the moderate correlation between AR symptom severity improvement and asthma symptom severity improvement.

The "one airway, one disease" hypothesis suggests joint management of AR and asthma leads to better control of both diseases \[[@CR31], [@CR32]\]. Evidence for the "one airway, one disease" hypothesis includes epidemiologic data that suggest the high frequency of comorbid asthma and AR, heritability of allergic diseases (e.g., AR, asthma, and atopic dermatitis), and the overlapping roles of inflammatory mediators in AR and asthma, which are supported by the clinical effectiveness of corticosteroids and antihistamines for both conditions. In this study, the moderate correlation between change of general AR-VAS and asthma-VAS scores lends additional credence to the "one airway, one disease" hypothesis.

Study limitations included the observational design and lack of a control group for comparative purposes. This limits comparison with previous studies, during which data were collected under different circumstances. Furthermore, we have limited data surrounding clinically relevant features of asthma, including the method by which asthma was diagnosed and current asthma medications. However, because of the multinational, noninterventional study design, information about a variety of patients' allergy characteristics could be obtained, and comparison through a preintervention and postintervention design was recorded. Although the 2-week study period was sufficient for documenting a substantial improvement in AR and asthma symptom severity, monitoring of AR symptom control over a longer period of time would better inform long-term outcomes with MP-AzeFlu treatment.

Conclusion {#Sec17}
==========

MP-AzeFlu use was associated with improved AR symptoms, asthma symptoms, and quality-of-life measures in patients with concomitant asthma. Change in overall AR symptoms and change in asthma symptoms were correlated. The results support the "one airway, one disease" therapy approach for asthma and AR management.
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